High induction dosing of risankizumab in patients with moderate-to-severe plaque psoriasis: Interim results from the phase 2 KNOCKOUT study

被引：0
|
作者：
Blauvelt, A. [1 ]
Gudjonsson, J. [2 ]
Matheson, R. [1 ]
Liu, R. [3 ]
Shi, L. [3 ]
Photowala, H. [3 ]
Ehst, B. [1 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Michigan, Dept Dermatol, Sch Med, Ann Arbor, MI USA
[3] AbbVie Inc, N Chicago, IL USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2023年 / 143卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
LB1703
引用
收藏
页码：B16 / B16
页数：1
相关论文
共 50 条
  • [41] Effects of apremilast on pruritus in patients with moderate-to-severe plaque psoriasis: results from the ESTEEM 1 and 2 trials
    Papp, K.
    Yosipovitch, G.
    Bagel, J.
    Kircik, L.
    Thaci, D.
    Lambert, J.
    Ferrandiz, C.
    Goodfield, M.
    Hu, C. C.
    Stevens, R.
    Day, R.
    Girolomoni, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E144 - E145
  • [42] Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study
    Li Xia
    Zheng Jie
    Pan WeiLi
    Zheng Min
    Lu Yan
    Li FuQiu
    Ding YangFeng
    Zhang JianZhong
    Li HongYing
    Rui WenLong
    国际皮肤性病学杂志（英文）, 2022, 05 (04)
  • [43] Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
    Rui, Wenlong
    Li, Xia
    Zheng, Jie
    Pan, Weili
    Zheng, Min
    Lu, Yan
    Li, Fuqiu
    Ding, Yangfeng
    Zhang, Jianzhong
    Li, Hongying
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB55 - AB55
  • [44] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Gordon, K. B.
    Blauvelt, A.
    Papp, K. A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Reich, K.
    Amato, D.
    Ball, S. G.
    Braun, D. K.
    Cameron, G. S.
    Erickson, J.
    Konrad, R. J.
    Muram, T. M.
    Nickoloff, B. J.
    Osuntokun, O. O.
    Secrest, R. J.
    Zhao, F.
    Mallbris, L.
    Leonardi, C. L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 345 - 356
  • [45] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
    Egeberg, Alexander
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2101 - 2102
  • [46] Efficacy and safety of risankizumab, an interleukin-23 inhibitor, in patients with moderate-to-severe chronic plaque psoriasis: 16-week results from the phase III IMMhance trial
    Blauvelt, A.
    Papp, K. A.
    Gooderham, M.
    Langley, R. G.
    Leonardi, C.
    Lacour, J. -P.
    Philipp, S.
    Tyring, S.
    Bukhalo, M.
    Wu, J. J.
    Bagel, J.
    Frankel, E. H.
    Pariser, D.
    Flack, M.
    Scherer, J.
    Geng, Z.
    Gu, Y.
    Camez, A.
    Thompson, E. H. Z.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E248 - E248
  • [47] Efficacy of guselkumab in patients with moderate-to-severe plaque psoriasis with involvement of the scalp, nails, hands, and feet: Results from the phase 3 VOYAGE 2 study
    Reich, Kristian
    Armstrong, April W.
    Foley, Peter
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    Shen, Yaung-Kaung
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [48] WORK PRODUCTIVITY IN BRAZILIAN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
    Lopes, N.
    Antonio, J. R.
    Fabricio, L.
    Azulay-Abulafia, L.
    Dias, L. L.
    Pertel, P.
    VALUE IN HEALTH, 2017, 20 (09) : A902 - A902
  • [49] Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis
    Tina Bhutani
    John Koo
    Jayme Heim
    Neal Bhatia
    Jacob Mathew
    Thomas Ferro
    J. Gabriel Vasquez
    Dermatology and Therapy, 2024, 14 : 1019 - 1025
  • [50] Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis
    Bhutani, Tina
    Koo, John
    Heim, Jayme
    Bhatia, Neal
    Mathew, Jacob
    Ferro, Thomas
    Vasquez, J. Gabriel
    DERMATOLOGY AND THERAPY, 2024, 14 (04) : 1019 - 1025
12345